Table 1.
<1 year (n = 45) | 1 to <2 years (n = 58) | ≥2 years (n = 340) | P value | |
---|---|---|---|---|
n (%) | n (%) | n (%) | ||
Sex | ||||
Male | 20 (44.4) | 32 (55.1) | 186 (54.7) | 0.419 |
Female | 25 (55.5) | 26 (44.8) | 154 (45.2) | |
WBC at diagnosis (/μL) | ||||
<10,000 | 8 (17.7) | 20 (34.4) | 128 (37.6) | 0.051 |
10,000–50,000 | 25 (55.5) | 23 (39.6) | 117 (34.4) | |
>50,000 | 12 (26.6) | 15 (25.8) | 95 (27.9) | |
FAB classification | ||||
M0 | 0 (0.0) | 0 (0.0) | 8 (2.3) | <0.001 |
M1 | 2 (4.4) | 3 (5.1) | 52 (15.2) | |
M2 | 1 (2.2) | 2 (3.4) | 114 (33.5) | |
M3 | 1 (2.2) | 0 (0.0) | 0 (0.0) | |
M4 | 3 (6.6) | 4 (6.8) | 40 (11.7) | |
M4Eo | 1 (2.2) | 5 (8.6) | 9 (2.6) | |
M5a | 15 (33.3) | 11 (18.9) | 49 (14.4) | |
M5b | 4 (8.8) | 4 (6.8) | 11 (3.2) | |
M6 | 0 (0.0) | 5 (8.6) | 5 (1.4) | |
M7 | 14 (31.1) | 21 (36.2) | 13 (3.8) | |
RAEBa | 1 (2.2) | 1 (1.7) | 1 (0.2) | |
RAEB-Ta | 1 (2.2) | 2 (3.4) | 36 (10.5) | |
ND | 2 (4.4) | 0 (0.0) | 2 (0.5) | |
Cytogenetic characteristics | ||||
t(8;21) | 0 (0.0) | 1 (1.7) | 121 (35.5) | <0.001 |
inv(16) | 1 (2.2) | 6 (10.3) | 25 (7.3) | |
t(9;11) | 8 (17.7) | 9 (15.5) | 22 (6.4) | |
Other 11q23 abnormalities | 11 (24.4) | 4 (6.8) | 15 (4.4) | |
t(6;9) | 0 (0.0) | 0 (0.0) | 3 (0.8) | |
inv(3) | 0 (0.0) | 0 (0.0) | 2 (0.5) | |
t(1;22) | 3 (6.6) | 0 (0.0) | 0 (0.0) | |
t(7;12) | 2 (4.4) | 1 (1.7) | 0 (0.0) | |
Normal karyotype | 6 (13.3) | 6 (10.3) | 68 (20.0) | |
Others | 13 (28.8) | 31 (53.4) | 82 (24.1) | |
ND | 1 (2.2) | 0 (0.0) | 2 (0.5) | |
FLT3-ITD status | ||||
Positive | 0 (0.0) | 3 (5.1) | 44 (12.9) | 0.002 |
Negative | 44 (97.7) | 55 (94.8) | 296 (87.0) | |
ND | 1 (2.2) | 0 (0.0) | 0 (0.0) |
WBC white blood cell count, FAB French–American–British, RAEB refractory anemia with excess blasts, RAEB-T refractory anemia with excess blasts in transformation, ND not detected, ITD internal tandem duplications
aAs the World Health Organization classification (3rd edition) was used, patients with <30 % bone marrow blasts were included in this study